Autolus Therapeutics (NASDAQ:AUTL) Trading Up 13.5% Following Analyst Upgrade

Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL) shot up 13.5% on Monday after Needham & Company LLC raised their price target on the stock from $10.00 to $11.00. Needham & Company LLC currently has a buy rating on the stock. Autolus Therapeutics traded as high as $1.89 and last traded at $1.8950. 2,745,350 shares traded hands during trading, an increase of 11% from the average session volume of 2,479,643 shares. The stock had previously closed at $1.67.

Other equities analysts also recently issued research reports about the company. William Blair reiterated an “outperform” rating on shares of Autolus Therapeutics in a report on Wednesday, September 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen cut Autolus Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Saturday, November 15th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Autolus Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $8.67.

Institutional Investors Weigh In On Autolus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. R Squared Ltd increased its position in shares of Autolus Therapeutics by 40.1% during the third quarter. R Squared Ltd now owns 30,476 shares of the company’s stock worth $50,000 after acquiring an additional 8,730 shares during the period. Tema Etfs LLC increased its stake in shares of Autolus Therapeutics by 9.0% during the second quarter. Tema Etfs LLC now owns 120,388 shares of the company’s stock worth $274,000 after purchasing an additional 9,960 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in Autolus Therapeutics by 41.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,419 shares of the company’s stock valued at $88,000 after buying an additional 11,289 shares in the last quarter. Invesco Ltd. lifted its stake in shares of Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock valued at $51,000 after purchasing an additional 11,381 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of Autolus Therapeutics by 63.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 30,432 shares of the company’s stock valued at $69,000 after buying an additional 11,821 shares in the last quarter. Institutional investors own 72.83% of the company’s stock.

Autolus Therapeutics Trading Up 12.0%

The firm has a 50 day moving average price of $1.49 and a 200-day moving average price of $1.78. The firm has a market cap of $497.68 million, a PE ratio of -2.25 and a beta of 2.01.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.07). Autolus Therapeutics had a negative return on equity of 63.76% and a negative net margin of 439.69%.The business had revenue of $21.19 million for the quarter, compared to analyst estimates of $21.08 million. Equities analysts forecast that Autolus Therapeutics PLC Sponsored ADR will post -0.94 earnings per share for the current fiscal year.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.